{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:29:21Z","timestamp":1784698161677,"version":"3.55.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T00:00:00Z","timestamp":1554681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4,8]]},"DOI":"10.1093\/ajhp\/zxz013","type":"journal-article","created":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T09:01:18Z","timestamp":1554714078000},"page":"505-511","source":"Crossref","is-referenced-by-count":16,"title":["Use of specific anti-Xa levels in acute kidney injury to transition patients from oral factor Xa inhibitors to i.v. heparin infusion"],"prefix":"10.1093","volume":"76","author":[{"given":"Sara","family":"Zochert","sequence":"first","affiliation":[{"name":"Sanford USD Medical Center, Sioux Falls, SD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiara M","family":"Oltman","sequence":"additional","affiliation":[{"name":"South Dakota State University College of Pharmacy and Allied Health Professions, Brookings, SD and Sanford USD Medical Center, Sioux Falls, SD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany M","family":"Elgersma","sequence":"additional","affiliation":[{"name":"South Dakota State University College of Pharmacy and Allied Health Professions, Brookings, SD and Sanford USD Medical Center, Sioux Falls, SD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thaddaus R","family":"Hellwig","sequence":"additional","affiliation":[{"name":"South Dakota State University College of Pharmacy and Allied Health Professions, Brookings, SD and Sanford USD Medical Center, Sioux Falls, SD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P","family":"Gulseth","sequence":"additional","affiliation":[{"name":"Sanford USD Medical Center, Sioux Falls, SD, and University of South Dakota Sanford School of Medicine, Sioux Falls, SD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,4,8]]},"reference":[{"key":"key\n\t\t\t\t2019040805010616700_CIT0001","author":"Baxter Healthcare Corporation"},{"key":"key\n\t\t\t\t2019040805010616700_CIT0002","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.2146\/ajhp150596","article-title":"Managing transitions from oral factor Xa inhibitors to unfractionated heparin infusions","volume":"73","author":"Faust","year":"2016","journal-title":"Am J Health-Syst Pharm."},{"key":"key\n\t\t\t\t2019040805010616700_CIT0003","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2146\/ajhp110725","article-title":"Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient","volume":"69","author":"Miyares","year":"2012","journal-title":"Am J Health-Syst Pharm."},{"key":"key\n\t\t\t\t2019040805010616700_CIT0004","doi-asserted-by":"crossref","first-page":"507","DOI":"10.37573\/9781585284900.021","article-title":"Coagulation laboratory considerations","volume-title":"Anticoagulation therapy: a clinical practice guide","author":"Gosselin","year":"2018","edition":"2"},{"key":"key\n\t\t\t\t2019040805010616700_CIT0005","article-title":"Institute of Safe Medication Practices. Acute care medication safety alert","year":"2017"},{"key":"key\n\t\t\t\t2019040805010616700_CIT0006","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/phar.1884","article-title":"Laboratory and clinical monitoring of direct acting oral anticoagulants: what clinicians need to know","volume":"37","author":"Conway","year":"2017","journal-title":"Pharmacotherapy."},{"key":"key\n\t\t\t\t2019040805010616700_CIT0007","volume-title":"Xarelto (rivaroxaban) package insert","year":"2019"},{"key":"key\n\t\t\t\t2019040805010616700_CIT0008","volume-title":"Eliquis (apixaban) package insert","year":"2018"},{"key":"key\n\t\t\t\t2019040805010616700_CIT0009","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1177\/1060028015578451","article-title":"Heparin-calibrated chromogenic anti-Xa activity measurements in patients receiving rivaroxaban: can this test be used to quantify drug level","volume":"49","author":"Gosselin","year":"2015","journal-title":"Ann Pharmacother."},{"key":"key\n\t\t\t\t2019040805010616700_CIT0010","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/1076029616629759","article-title":"Evaluation of a heparin-calibrated antifactor Xa assay for measuring the anticoagulant effect of oral direct Xa inhibitors","volume":"22","author":"Beyer","year":"2016","journal-title":"Clin Appl Thromb Hemost."},{"key":"key\n\t\t\t\t2019040805010616700_CIT0011","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2146\/ajhp150360","article-title":"Influence of apixaban on antifactor Xa levels in a patient with acute kidney injury","volume":"73","author":"Wendte","year":"2016","journal-title":"Am J Health-Syst Pharm."},{"key":"key\n\t\t\t\t2019040805010616700_CIT0012","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/psp4.12184","article-title":"Population pharmacokinetics, pharmacodynamics, and exploratory exposure-response analyses of apixaban in subjects treated for venous thromboembolism","volume":"6","author":"Byon","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"key":"key\n\t\t\t\t2019040805010616700_CIT0013","doi-asserted-by":"crossref","first-page":"35","DOI":"10.37573\/9781585284900.003","article-title":"Unfractionated heparin","volume-title":"Anticoagulation therapy: a clinical practice guide","author":"Dager","year":"2018","edition":"2"},{"key":"key\n\t\t\t\t2019040805010616700_CIT0014","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.joa.2015.08.001","article-title":"Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation","volume":"32","author":"Ikeda","year":"2016","journal-title":"J Arrhythm."},{"key":"key\n\t\t\t\t2019040805010616700_CIT0015","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/1060028017729481","article-title":"Influence of direct oral anticoagulants on anti-factor Xa measurements used for monitoring heparin","volume":"52","author":"Macedo","year":"2018","journal-title":"Ann Pharmacother."},{"key":"key\n\t\t\t\t2019040805010616700_CIT0016","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jacc.2014.05.065","article-title":"Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants","volume":"64","author":"Cuker","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"key\n\t\t\t\t2019040805010616700_CIT0017","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/bcp.12106","article-title":"Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects","volume":"76","author":"Frost","year":"2013","journal-title":"Br J Clin Pharmacol."},{"key":"key\n\t\t\t\t2019040805010616700_CIT0018","unstructured":"Kowalski K , NielsenJ, RoyAet al Exposure and anti-Xa activity in nonvalvular atrial fibrillation patients: an application of population PK\/PD analysis. Paper presented at 5th International Society of Pharmacometrics. Las Vegas, Nevada; 2014 Oct 12\u201315. Poster M-027."},{"key":"key\n\t\t\t\t2019040805010616700_CIT0019","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2165\/11595320-000000000-00000","article-title":"Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention","volume":"50","author":"Mueck","year":"2011","journal-title":"Clin Pharmacokinet."},{"key":"key\n\t\t\t\t2019040805010616700_CIT0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin Pharmacokinet."},{"key":"key\n\t\t\t\t2019040805010616700_CIT0021","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1477-9560-11-11","article-title":"Laboratory assessment of rivaroxaban: a review","volume":"11","author":"Samama","year":"2013","journal-title":"Thromb J."},{"key":"key\n\t\t\t\t2019040805010616700_CIT0022","volume-title":"Anti-Xa assay for heparin monitoring (August 1, 2016).","author":"MCL Education"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/76\/8\/505\/28272041\/zxz013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T18:09:54Z","timestamp":1721153394000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/76\/8\/505\/5427355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,8]]},"references-count":22,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,4,8]]},"published-print":{"date-parts":[[2019,4,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxz013","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,4,15]]},"published":{"date-parts":[[2019,4,8]]}}}